Enzychem Lifesciences

Developer of therapies for treating chemotherapy-induced neutropenia, oral mucositis, and psoriasis

placeSeoul, Seoul, South Korea calendar_todayFounded 1999 groups100 employees language enzychem.com

Innovation

54 patent families (22 granted) — focus: Human necessities, Chemistry & metallurgy, Emerging technologies, Physics & computing; filing pace slowing. Cited 1,571 times.

YearFilings
201510
201610
201714
201814
201917
202026
202121
202214
202311
20245
20255
20261

Investor mix

2 investors on record.

Investor typeCountShare
Venture capital150%
Other / undisclosed150%
Coming soon